Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash paid for interest	$ 36,202	$ 13,322	$ 15,456
Income taxes paid	61,129	0	0
Purchases of equipment financed through capital leases	355,144	84,650	0
Stock issuance of 167,086 shares in lieu of Directors' fees	0	184,653	0
Stock issuance in lieu of Directors' fees (in shares)		167,086
Deferred financing costs	27,236	20,449	0
Convertible Secured Promissory Notes issued in conjunction with the acquisition of Surgical Biologics	0	0	1,250,000
Warrants issued for placement fees associated with Senior Secured Promissory Notes	0	0	14,885
Beneficial conversion related to related party	0	514,456	80,000
Stock issuance of 5,250,000 shares in conjunction with acquisition of Surgical Biologics	0	0	7,087,500
Stock issued in conjunction with acquisition of Surgical Biologics (in shares)			5,250,000
Beneficial conversion related to convertible debt issued with regard to acquisition of Surgical Biologics	0	0	437,500
Stock issuance in connection of Earn-Out Liability of 1,174, 915 shares for 2013 and 2,632,576 shares for 2012	5,792,330	3,185,223	0
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt of 5,272,004 shares in 2013 and 406,664 shares in 2011	5,272,004	0	406,663
Stock issued for convertible debt (in shares)	5,272,004		406,664
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	0	1,403,630	0
Stock issued during period, shares, issued for payment of Line of Credit with related party (shares)		1,403,630
Stock issuance of 216,085 shares for exercise of cashless warrants	0	216	0
Shares issued for Cashless Exercise (in shares)		216,085
Secured Promissory Notes related to acquisition of Surgical Biologics	0	893,267	2,278,052
Stock issued related to acquisition of Surgical Biologics (in shares)	893,267	893,267	893,267
Tenant improvement incentive	996,866	0	0
Legal fees paid for public offering	101,694	0	0
Accounts payable
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	30,100	0	0
Accrued expenses
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	$ 62,396	$ 0	$ 0